

FIGURE 1A




FIGURE 1B




FIGURE 2

CD33+ AML Cells					Non-AML (CD33-) Cells				
Cell Line	CC-90009 IC50 (M)	CD33AB-Compound I(a) conjugate IC50 (M)		Mylotarg IC50 (M)	Cell Line	CC-90009 IC50 (M)	CD33AB-Compound I(a) conjugate IC50 (M)		Mylotarg IC50 (M)
MV-4-11	1.20E-08	9.00E-11		7.00E-11	RS4;11	4.50E-09	>2.00E-08		5.60E-10
ML-2	9.10E-09	9.00E-11		2.00E-11	CCRF-CEM	8.04E-09	>2.00E-08		8.56E-09
HL-60	7.84E-09	1.10E-10		9.00E-11	TALL-1	4.12E-09	>2.00E-08		2.92E-09
SKNO-1	4.94E-09	1.60E-10		4.00E-11	NALM-16	9.60E-09	>2.00E-08		8.02E-09
F-36P	3.69E-09	2.00E-10		>2.00E-08	Molt-4	1.13E-08	>2.00E-08		4.30E-10
Kasumi-6	>2.00E-08	3.40E-10		>2.00E-08	LC4-1	1.31E-08	>2.00E-08		1.47E-09
OCI-AML-4	8.26E-09	3.60E-10		1.00E-10	Reh	1.37E-08	>2.00E-08		5.80E-10
Molm-13	>2.00E-08	3.60E-10		3.00E-11	Loucy	4.07E-09	>2.00E-08		3.31E-09
AML-193	9.59E-09	4.30E-10		>2.00E-08	ATN-1	>2.00E-08	>2.00E-08		8.03E-09
EoL-1	1.18E-08	5.20E-10		3.00E-11	SUP-T1	>2.00E-08	>2.00E-08		8.61E-09
HNT-34	1.33E-09	1.01E-09		5.20E-10	SUP-B15	>2.00E-08	>2.00E-08		1.78E-09
Kasumi-3	1.16E-09	1.12E-08		>2.00E-08	Jurkat, Clone E6-1	>2.00E-08	>2.00E-08		1.02E-08
OCI-AML-1	6.44E-09	>2.00E-08		9.00E-11	THP-1	>2.00E-08	>2.00E-08		2.57E-09
KG-1a	1.27E-08	>2.00E-08		>2.00E-08	ARH-77	>2.00E-08	>2.00E-08		8.91E-09
NOMO-1	>2.00E-08	>2.00E-08		>2.00E-08	SKM-1	>2.00E-08	>2.00E-08		4.50E-10
KASUMI-1	>2.00E-08	>2.00E-08		>2.00E-08	Kopn-8	>2.00E-08	>2.00E-08		4.10E-10
OCI-M1	>2.00E-08	>2.00E-08		>2.00E-08	CMK-86	8.01E-09	>2.00E-08		>2.00E-08
PLB-985	1.72E-08	>2.00E-08		>2.00E-08	CMK-11-5	5.74E-09	>2.00E-08		>2.00E-08
					KU812	1.49E-08	>2.00E-08		>2.00E-08
					TF-1a	8.15E-09	>2.00E-08		>2.00E-08
					GDM-1	6.91E-09	>2.00E-08		>2.00E-08

Efficacy
Highly effective
Medium
Low

FIGURE 3





FIGURE 4



Sample	Gender	Age	Previous Treatments	Mutations
1	Male	31	1 st : Cytarabine, Idarubicin (7+3). Response: CR 2 nd : Cytarabine. Response: PD	IDH2 P140Q SRSF2 P95H
2	Male	83	Decitabine. Response: CR	NRAS Q61H/Q61K/G12D
3	Female	29	1 st : Cytarabine, Idarubicin (7+3). Response: PR 2 nd : Mitoxantrone, Etoposide, Cytarabine. Response: PD	NRAS Q61K KRAS G12V

FIGURE 5




FIGURE 6

MV4-11




FIGURE 7




FIGURE 8





FIGURE 9



MV411 Mouse Plasma: 3 mpk CD33AB-Compound I(a) Conjugate




FIGURE 10B




FIGURE 10A

